Explore New Cellular Frontiers

See the Power of Full Spectrum Flow Cytometry.

Cytek's Aurora and Northern Lights™ analyzers, as well as the Aurora CS sorter, have redefined what is possible in flow cytometry by delivering extraordinary resolution and assay flexibility. We have demonstrated 40 colors on a 5-laser Aurora system, making in-depth insights and statistically powerful numbers from rare sample populations a reality.

Vast experience designing various full spectrum panels has led us to a deeper understanding of how fluorochromes work together in increasingly complex panels and experiments. We are now applying this expertise to evaluate and select cFluor® dyes and antibody conjugates.

Turnkey Solutions. Simplified Workflows.

When used with Cytek® full spectrum flow cytometers, cFluor immunoprofiling kits provide turnkey solutions for both basic and in-depth research needs in immunophenotyping of human PBMC and whole blood. Users with different levels of expertise are now empowered to get optimal results.

Break free from time-consuming, labor-intensive, costly panel design and optimization with pre-optimized kits from Cytek.

cFluor Reagent Kits 8, 14, and 25 color options now available

Discover More

https://welcome.cytekbio.com/fsp2021

Check for updates

European Journal of Immunology

Letter to the Editor

[DOI: 10.1002/eji.202149315]

Ex vivo microRNA and gene expression profiling of human Tr1-like cells suggests a role for miR-92a and -125a in the regulation of EOMES and IL-10R

Regulatory T-cells, comprising both FOXP3$^+$Tregs and FOXP3$^-$ type-1 regulatory T-cells (Tr1), are required to maintain immune homeostasis. We previously identified a population of human IL-10 and IFN-γ co-producing Tr1-like cells, which are involved in graft-versus-host disease, colitis, autoimmunity, and cancer [1–5]. They express the transcription factor eomesodermin (EOMES) [2,6], which is characteristic for cytotoxic T-lymphocytes (CTL) and controls IFN-γ production and cytotoxic functions [7]. T-bet expression, differentiation requirements, and clonotype sharing suggests that EOMES$^+$ Tr1-like cells are derived from Th1-cells [2,5,6]. MicroRNAs (miRNAs) regulate gene expression and shape differentiation states, and are required for the functions of FOXP3$^+$ Tregs [8]. The role of miRNAs in the biology of Tr1-like cells is in contrast largely unknown.

Since different subsets of human CD4$^+$T-cells express EOMES [2], we asked how they were molecularly related. We purified EOMES-expressing CD4$^+$ T-cell subsets, that is, Th1 effector memory cells (Th1$_{EM}$), CD4$^+$CTL, and Tr1-like cells ex vivo from peripheral blood of healthy donors according to an established gating strategy [2] (Supporting Information Fig. 1A) and performed gene expression analysis. Th1 central memory cells (Th1$_{CM}$), which largely lacked EOMES expression (Supporting Information Fig. 1B), were analyzed as control. We identified 424 differentially expressed genes ($p < 0.01$, Supporting Information Table 1). Hierarchical clustering revealed limited donor-to-donor variability (Fig. 1A), suggesting that the analyzed subsets represent conserved differentiation stages. This analysis resulted in one major cluster containing all EOMES-expressing subsets, and a second cluster containing Eomes$^-$Th1$_{CM}$. In the EOMES$^+$ subcluster, Tr1-like cells clustered together with CTL. Notably, principal component analysis (PCA) positioned Th1$_{CM}$ and CTLs at opposite sites of the three-dimensional space, and Tr1-like cells were positioned between Th1$_{EM}$ and CTL (Fig. 1B), suggesting that they represent an intermediate differentiation state. Indeed, the majority of differentially expressed genes were downregulated in Tr1-like cells as compared to Th1-cells, but upregulated as compared to CTL (Supporting Information Fig. 1C and Table 2). Tr1-like cells expressed higher levels of GZMK as compared to Th1$_{CM}$ and CTL, and of IL-10R as compared to Th1-cells. Moreover, they expressed higher levels of *EOMES*, *GZMA*, *NKG7*, *CCL5*, and *HLA-G* as compared to Th1$_{CM}$, but had downregulated *FOXO1* and *LTA*. CD4$^+$CTL expressed the lowest levels of *CCR7*, *CD27*, and *LEF1*, suggesting that they are terminally differentiated effector cells. Selected differentially expressed genes and relevant controls were then measured by RT-qPCR in independent donors (Supporting Information Fig. 2A). *GZMK* and *EOMES* were highly expressed in Tr1-like cells, as expected [2]. *IFNG* mRNA was constitutively expressed in CTL and Tr1-like cells, whereas *IL10* and *GZMB* mRNA were largely restricted to Tr1-like cells and CD4$^+$CTL, respectively. miRNA expression in human CD4$^+$ T-cell subsets is superior compared to gene expression patterns to map CD4$^+$ T-cell differentiation stages [9]. We therefore analyzed the expression of 664 miRNAs in the same T-cell subsets. Twelve miRNAs were found to be differentially expressed, as detected by TaqMan miRNA arrays (Fig. 1C; Supporting Information Table 3). Hierarchical clustering revealed again that Tr1-like cells clustered together with CD4$^+$CTLs. Most of the differentially expressed miRNAs were downregulated in Tr1-like cells and in CTL. Three of these miRNAs were highly expressed in Th1$_{CM}$, suggesting that they might be involved in repressing cytotoxic cell fates. Conversely, miR-186, miR-194, and miR-345 were highly expressed, although not uniquely, in Tr1-like cells. Validation of selected miRNAs by RT-qPCR in independent donors confirmed downregulation of miR-150, miR-31, and, most notably, miR-92a and miR-125a in Tr1-like cells (Fig. 1D). Inspection of the putative targets using TargetScan revealed that both miR-125a and miR-92a targeted Tr1-expressed genes. Specifically, the intersection of differentially expressed genes with the top 500 TargetScan predicted targets (irrespective of site conservation) of the miR-125 family and of miR-92a-3p identified genes involved in Tr1-like cell biology.

Correspondence: Silvia Monticelli; Jens Geginat
e-mail: silvia.monticelli@irb.usi.ch; geginat@ingm.org

© 2021 The Authors. *European Journal of Immunology* published by Wiley-VCH GmbH

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.



Figure 1. Gene expression and miRNome analysis of human EOMES$^+$CD4$^+$ T-cell subsets. **(A)** Hierarchical clustering of differentially expressed genes in EOMES$^+$ Tr1-like cells ($n = 3$), CD4$^+$CTL, Th1$_{CM}$, and Th1$_{EM}$ ($n = 4$) according to one-way ANOVA ($p < 0.01$). **(B)** Three-dimensional PCA of selectively expressed genes. **(C)** Hierarchical clustering of 12 miRNAs expressed in Th1$_{CM}$, Th1$_{EM}$, CD4$^+$CTL, and Tr1-like subsets, selected by one-way ANOVA ($p < 0.01$). Data, normalized on global mean, are presented as z-scores calculated on ΔCt. **(D)** Differential expression of four selected miRNAs (miR-31 ($n = 7$), miR-125a-5p ($n = 8$), miR-150 ($n = 9$), and miR-92a ($n = 5$)) in independent donors were analyzed by RT-qPCR (data represented as $2^{-\Delta Ct}$). Statistical analysis was performed using a one-way ANOVA and Tukey post-test between four groups: Th1$_{CM}$, Th1$_{EM}$, CTL, and Tr1 (*$p < 0.05$; **$p < 0.01$; ***$p < 0.001$).

Thus, putative targets of the miR-125 family included *IL10RA*, while a putative target of miR-92a was *EOMES* (Fig. 2A). The 3'-untranslated region (3'UTR) of the *EOMES* mRNA contains a putative miR-92a responsive element (Supporting Information Fig. 2B). We therefore performed dual luciferase assay to assess whether this region was a target of miR-92a. Upon transfection in HEK-293T-cells, a synthetic miR-92a mimic oligonucleotide significantly reduced luciferase expression from a reporter plasmid containing the 3'UTR of the human *EOMES* gene, as compared to a scrambled control oligonucleotide (Fig. 2B). To investigate whether miR-92a could affect EOMES protein expression in primary human T-lymphocytes, we isolated CCR5$^+$CD4$^+$T-cells, which are enriched for Eomes$^+$ cells (Supporting Information Fig. 2C). After transfection with either a miR-92a mimic or scrambled control oligonucleotide, the levels of EOMES protein expression were moderately, but consistently, reduced (Supporting Information Fig. 2D), suggesting that this miRNA could indeed suppress EOMES expression in CD4$^+$T-cells. Next, we focused on miR-125a. Notably, its closely related family member miR-125b is expressed exclusively in naïve CD4$^+$T-cells [9] (Fig. 2C). Conversely, miR-125a was also expressed in Th1-cells, but remained low in CTL and Tr1-like cells. The seed sequences (nucleotide 2-to-7 of the miRNAs, responsible for target specificity) of miR-125a and miR-125b are identical, as expected for a miRNA family, suggesting that they possess similar target specificities. Therefore, potential differences in their mRNA targeting are rather due to their different expression patterns. The

© 2021 The Authors. *European Journal of Immunology* published by Wiley-VCH GmbH



Figure 2. Identification of putative gene targets of miR-92a and miR125a. (A) Venn Diagram showing the overlap between differentially expressed genes and the miRNA targets predicted by TargetScan. **(B)** Dual-luciferase assay in HEK-293T cells transfected with the human *EOMES* 3'UTR together with miR-92a or a scrambled control. Mean of three independent experiments with six to nine technical replicates. Statistical analysis was performed using a Wilcoxon matched-pairs signed rank test (*$p < 0.05$). Error bars show median and interquartile range. **(C)** Expression of miR-125a and miR-125b in the indicated CD4$^+$ T-cell subsets was measured by RT-qPCR (3 independent donors analyzed in 3 experiments). **(D)** IL-10Rα protein levels in gated CD4$^+$CTL, Tr1-, Th1$_{EM}$, and Th1$_{CM}$-cells and measured by flow cytometry ($n = 6$, 1 experiment). Shown is the MFI; Fluorescence minus one was used as negative control. the statistical analysis was performed using a one-way ANOVA. **(E)** Dual-luciferase assay in HEK-293T cells transfected with the human *IL-10RA* 3'UTR together with a miR-125a or scrambled control. Data show four independent experiments with three to four technical replicates. Error bars show median and interquartile range. Statistical analysis was performed using a Kruskal-Wallis test (**$p < 0.005$).

IL-10R is highly expressed on regulatory T-cells, including Tr1-like cells (Fig. 2D; Supporting Information Fig. 2E), and it is required to maintain IL-10 production and suppressive capabilities [10]. Moreover, the *IL10RA* gene was shown to be targeted by miR-125b in human CD4$^+$ T-cells [9]. To assess the ability of miR-125a to regulate the expression of *IL10RA*, we performed luciferase reporter assay using a plasmid containing the 3'UTR of this gene, either wild-type or mutated in the region complementary to the miR-125 seed sequence [9]. Co-transfection of miR-125a strongly and significantly reduced reporter expression from the wild-type, but not from the mutated, 3'UTR (Fig. 2E). To assess the role of miR-125a in primary human T-cells, we transfected CD4$^+$CD45RA$^-$ memory T-cells with either a miR-125a mimic, an antagomir to inhibit miR-125a activity or with scrambled controls. After 2 days, the expression of miR-125a was strongly elevated in miR-125-mimic transfected cells, and diminished upon antagomir transfection (Supporting Information Fig. 2F). Under these conditions we monitored the expression of the predicted targets by RT-qPCR and by flow cytometry. Both IFN-γ and IL-10Rα were slightly reduced both at the mRNA and protein level upon transfection with the miR-125a-mimic, and were instead slightly elevated with the miR-125a antagomir (Supporting Information Fig. 2G). In conclusion, by performing gene expression and miRNA profiling of *ex vivo* isolated human EOMES$^+$Tr1-like cells, we provide additional evidence that Tr1-like cells are a unique T-cell subset. Moreover, our data suggests that miR-92a and miR-125a target the expression of Tr1-associated genes like *EOMES* and *IL-10R*, and might thus act as inhibitors of Tr1 differentiation.

© 2021 The Authors. *European Journal of Immunology* published by Wiley-VCH GmbH



Marco De Simone[1], Michele Chirichella[2], Stefan Emming[2], Saveria Mazzara[1], Valeria Ranzani[1], Paola Gruarin[1], Giorgia Moschetti[1], Nadia Pulvirenti[1], Stefano Maglie[1], Chiara Vasco[1], Maria Cristina Crosti[1], Grazisa Rossetti[1,3], Massimiliano Pagani[1,3,4], Sergio Abrignani[1,5], Silvia Monticelli[2] and Jens Geginat[1,5]

[1] Istituto Nazionale Genetica Molecolare INGM 'Romeo ed Enrica Invernizzi', Milan, Italy
[2] Institute for Research in Biomedicine (IRB), Università della Svizzera italiana (USI), Bellinzona, Switzerland
[3] FIRC Institute of Molecular Oncology (IFOM), Milan, Italy
[4] Department of Medical Biotechnology and Translational Medicine, Università degli Studi, Milano, Italy
[5] Department of Clinical Sciences and Community Health, Università degli Studi, Milano, Italy

Acknowledgments: We thank F. Clemente for statistical analysis. J.G. received grants from the Cariplo Foundation (2013-0937), from the Fondazione Italiana Sclerosi Multipla (FISM, 2017/R/14) and the Associazione Italiana Ricerca sul Cancro (AIRC, IG 2019 Id 23581). This work was also supported by the Swiss National Science Foundation grant 175569 to S.M.

Conflict of interest: The authors declare no commercial or financial conflict of interest.

Peer review: The peer review history for this article is available at https://publons.com/publon/10.1002/eji.202149315

References

1 **Häringer, B.** et al., *J. Exp. Med.* 2009. **206**(5): 1009–1017.

2 **Gruarin, P.** et al., *Eur. J. Immunol.* 2019. **49**(1): 96–111.

3 **Alfen, J. S.** et al., *J. Allergy Clin. Immunol.* 2018. 1537–1547.e8.

4 **Facciotti, F.** et al., *J. Allergy Clin. Immunol.* 2016. **137**(1): 318–321.e5.

5 **Bonnal, R J. P.** et al., *Nat. Immunol.* 2021. **22**(6): 735–745.

6 **Zhang, P.** et al., *Sci Immunol* 2017. **2**(10): eaah7152.

7 **Pearce, E. L.**, *Science* 2003. **302**(5647): 1041–1043.

8 **Monticelli, S.**, *Semin. Immunol.* 2013. **25**(4): 291–298.

9 **Rossi, R. L.** et al., *Nat. Immunol.* 2011. **12**(8): 796–803.

10 **Brockmann, L.** et al., *J. Immunol.* 2017. **198**(3): 1130–1141.

Abbreviations: **3'-UTR**: 3'-untranslated region · **CTL**: cytotoxic T-lymphocytes · **EOMES**: eomesodermin · **miRNA**: microRNA · **Tr1**: FOXP3⁻ type-1 regulatory T-cells

Keywords: Tr1-like cells • microRNAs • EOMES • IL-10R

Full correspondence: Silvia Monticelli, Institute for Research in Biomedicine (IRB), Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland
e-mail: silvia.monticelli@irb.usi.ch
Jens Geginat, stituto Nazionale Genetica Molecolare INGM 'Romeo ed Enrica Invernizzi', Milan 20122, Italy
e-mail: geginat@ingm.org

Received: 22/4/2021
Revised: 26/7/2021
Accepted: 13/9/2021
Accepted article online: 15/9/2021

Additional supporting information may be found online in the Supporting Information section at the end of the article.

© 2021 The Authors. *European Journal of Immunology* published by Wiley-VCH GmbH